Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations

January 29, 2021 Auto Bot amivantamab, Clinical Trials, EGFR, Janssen, Metastatic, Non-Small Cell Lung Cancer, P-I, reports, Result, Study, Unresectable 0

Shots:

  • The P-I CHRYSALIS study involves assessing of amivantamab (RP2D of 1050 mg [1400 mg for a patient weight of ≥80 kg]) as a monothx. and in combination with lazertinib in 460 patients with metastatic or unresectable NSCLC and EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based CT
  • Results: ORR (40%); mPFS (8.3 mos.); mOS (22.8 mos.), clinical benefit rate (74%), mDoR (11.1 mos.). The data showed robust activity and durable responses with a tolerable and manageable safety profile
  • The company has filed regulatory submissions in the US and EU seeking approval of amivantamab

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: The Pharma Letter

The post Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations first appeared on PharmaShots.